CA
JBIO

CoreCap Advisors’s Jade Biosciences JBIO Stock Holding History

CoreCap Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19
Closed -$1.68K – 2798
2025
Q1 		$1.68K Buy
19
+13
+217% +$1.14K ﹤0.01% 2410
2024
Q4 		$596 Buy
+6
New +$517 ﹤0.01% 2464

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

CoreCap Advisors's JBIO Position: Q2 2025 in Review

CoreCap Advisors sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 19 shares — an estimated $1.68K sold.

CoreCap Advisors first reported a position in JBIO in Q4 2024 and held it in 2 quarters. The position peaked at $1.68K in Q1 2025. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • CoreCap Advisors reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 19 Jade Biosciences shares in Q2 2025, an estimated $1.68K.
  • CoreCap Advisors first reported a position in Jade Biosciences in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Jade Biosciences position peaked at $1.68K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.